National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021
USA117th CongressHR-4369| House
| Updated: 10/20/2021
Frank Pallone
Democratic Representative
New Jersey
Cosponsors (1)
Health, Education, Labor, and Pensions Committee, Health Subcommittee, Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021 This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education (or consortia of such institutions) as National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on advanced and continuous pharmaceutical manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Bill from Previous Congress
HR 116-4866National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Subcommittee Consideration and Mark-up Session Held.
Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
Ordered to be Reported (Amended) by Voice Vote.
Committee Consideration and Mark-up Session Held.
Placed on the Union Calendar, Calendar No. 111.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-151.
Mr. Pallone moved to suspend the rules and pass the bill, as amended.
Considered under suspension of the rules. (consideration: CR H5645-5647)
DEBATE - The House proceeded with forty minutes of debate on H.R. 4369.
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Considered as unfinished business. (consideration: CR H5662-5663)
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 368 - 56 (Roll no. 318). (text: CR H5645-5647)
View VoteMotion to reconsider laid on the table Agreed to without objection.
The title of the measure was amended. Agreed to without objection.
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Health
Advanced technology and technological innovationsCongressional oversightDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationFood and Drug Administration (FDA)Government information and archivesHealth programs administration and fundingHealth technology, devices, suppliesHigher educationManufacturingPrescription drugsProduct development and innovationResearch administration and fundingResearch and development
National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021
USA117th CongressHR-4369| House
| Updated: 10/20/2021
National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021 This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education (or consortia of such institutions) as National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on advanced and continuous pharmaceutical manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Bill from Previous Congress
HR 116-4866National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Subcommittee Consideration and Mark-up Session Held.
Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
Ordered to be Reported (Amended) by Voice Vote.
Committee Consideration and Mark-up Session Held.
Placed on the Union Calendar, Calendar No. 111.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-151.
Mr. Pallone moved to suspend the rules and pass the bill, as amended.
Considered under suspension of the rules. (consideration: CR H5645-5647)
DEBATE - The House proceeded with forty minutes of debate on H.R. 4369.
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Considered as unfinished business. (consideration: CR H5662-5663)
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 368 - 56 (Roll no. 318). (text: CR H5645-5647)
View VoteMotion to reconsider laid on the table Agreed to without objection.
The title of the measure was amended. Agreed to without objection.
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Frank Pallone
Democratic Representative
New Jersey
Cosponsors (1)
Health, Education, Labor, and Pensions Committee, Health Subcommittee, Energy and Commerce Committee
Health
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Advanced technology and technological innovationsCongressional oversightDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationFood and Drug Administration (FDA)Government information and archivesHealth programs administration and fundingHealth technology, devices, suppliesHigher educationManufacturingPrescription drugsProduct development and innovationResearch administration and fundingResearch and development